# A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Study · id `cardio:ct-nct05702034` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05702034](<https://clinicaltrials.gov/study/NCT05702034>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05702034

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 12523 participants.

## Technical summary

Registry record NCT05702034. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-15 (actual); primary completion 2026-10-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 12523 participants (enrolled count; ClinicalTrials.gov record NCT05702034, source copy `cardio:ctgov-nct05702034-2026-09-25`, retrieved 2026-10-26)
- Started: 2023-02-15 (actual) (ClinicalTrials.gov record NCT05702034, source copy `cardio:ctgov-nct05702034-2026-09-25`, retrieved 2026-10-26)
- Primary completion: 2026-10-15 (anticipated) (ClinicalTrials.gov record NCT05702034, source copy `cardio:ctgov-nct05702034-2026-09-25`, retrieved 2026-10-26)
- Completion: 2026-10-15 (anticipated) (ClinicalTrials.gov record NCT05702034, source copy `cardio:ctgov-nct05702034-2026-09-25`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Croatia; Czechia; Denmark; Estonia; Finland; France; Germany; Greece; Hong Kong SAR China; Hungary; India; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Philippines; Poland; Portugal; Romania; Serbia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; United Kingdom; Vietnam (ClinicalTrials.gov record NCT05702034, source copy `cardio:ctgov-nct05702034-2026-09-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05702034-2026-09-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
- Acronym: LIBREXIA-STROK
- Condition: Ischemic Stroke; Ischemic Attack, Transient
- Intervention (Drug): Milvexian
- Intervention (Drug): Placebo
- Lead sponsor: Janssen Research & Development, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol Myers Squibb Company (BMS)
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Janssen Research & Development, LLC (`cardio:org-janssen-research-development-llc`)

## Provenance

Content hash: b3c7b78f397e6d3aa6a12d30f1f5d72f691853e962e6ea8c4be920874b9efcbd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
